Results 11 to 20 of about 352,135 (348)
Epigenetics in myeloproliferative neoplasms
Frontiers in Oncology, 2023 The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis.
Graeme Greenfield, Mary Frances McMullin
doaj +5 more sources
Molecular pathogenesis of the myeloproliferative neoplasms [PDF]
Journal of Hematology & Oncology, 2021 The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera, essential thrombocythaemia and primary myelofibrosis.
G. Greenfield, M. McMullin, K. Mills
semanticscholar +6 more sources
Myelodysplastic/Myeloproliferative Neoplasms [PDF]
American Journal of Clinical Pathology, 2009 AbstractMyelodysplastic/myeloproliferative neoplasms (MDS/MPNs) are rare de novo myeloid neoplasms that exhibit hybrid dysplastic and proliferative features at presentation. This SHP/EAHP Workshop session was uniquely problematic owing to the overlap between MDS/MPNs and both chronic myeloproliferative neoplasms and myelodysplasia.
Kathryn Foucar
openalex +4 more sources
The Microenvironment in Myeloproliferative Neoplasms [PDF]
Hematology/Oncology Clinics of North America, 2021 Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN.
Ramanathan, Gajalakshmi +1 more
openaire +4 more sources
Biomarker Research, 2021 Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 represent the biomarkers of WHO-defined ...
Simone Romagnoli +11 more
doaj +1 more source
Genetic basis and molecular profiling in myeloproliferative neoplasms
Blood, 2022 Visual ...
D. Luque Paz, R. Kralovics, R. Skoda
semanticscholar +1 more source
JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
Pharmaceuticals, 2022 The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN).
Michael Bader, S. Meyer
semanticscholar +1 more source
Aetiology of Myeloproliferative Neoplasms [PDF]
Cancers, 2020 Myeloproliferative neoplasms (MPNs) have estimated annual incidence rates for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis of 0.84, 1.03, and 0.47 per 100,000. Prevalence is much higher, particularly for PV and ET, as mortality rates are relatively low.
Mary Frances McMullin +1 more
openaire +5 more sources